Rebecca Carr, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 22899 Weather Vane Ct, Mattawan, MI 49071 Phone: 612-226-4803 |
Keynote Pediatric Speech And Language Therapy Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 22899 Weather Vane Ct, Mattawan, MI 49071 Phone: 612-226-4803 |
News Archive
Celgene Corporation announced non-GAAP net income of $294.6 million, or non-GAAP diluted earnings per share of $0.63 for the quarter ended March 31, 2010. Non-GAAP net income for the first quarter of 2009 was $205.1 million or non-GAAP diluted earnings per share of $0.44. Based on U.S. GAAP, Celgene reported net income of $234.4 million, or diluted earnings per share of $0.50 for the quarter ended March 31, 2010. GAAP net income for the first quarter of 2009 was $162.9 million, or diluted earnings per share of $0.35.
Researchers from Salk have found that two experimental drugs named CMS121 and J147 may improve memory functions and reduce the progression of memory decline and brain degeneration in mice models of Alzheimer's disease (AD). The researchers published their work in the latest issue of the journal eLife. The study was titled, "Elevating acetyl-CoA levels reduces aspects of brain aging."
Tragic miscarriages for a couple have led to a discovery with potentially broad implications for future disease treatments, according to a team of researchers at the University of North Carolina School of Medicine. They identified a previously undiscovered gene mutation underlying hydrops fetalis – a fatal condition to fetuses due to fluid buildup in the space between organs.
Roll Call: The death of Sen. Robert Byrd, D-W. Va., has jeopardized further the passage of some bills in Congress, including a bill that would extend unemployment benefits. "Democratic leaders have been thwarted numerous times in recent weeks on jobs legislation, despite scaling down the measure dramatically after Republicans and some moderate Democrats balked at adding to the deficit.
Merck & Co., Inc. today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which excludes purchase accounting adjustments, merger-related expenses, restructuring costs and the gain on AstraZeneca's asset option exercise. Second-quarter GAAP EPS was $0.24.
› Verified 3 days ago